Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care news included CMS' proposal to cover chimeric antigen receptor T-cell therapy; a study faulting the FDA’s handling of fentanyl oversight; and breast surgeons calling for genetic testing for all patients with breast cancer.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Read more about the stories in this podcast:
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
Study Criticizes FDA Safety Oversight of Rapid-Release Fentanyl
Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer
Greater Diet Drink Consumption Heightens Stroke Risk in Postmenopausal Women
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More